acute poisoning
Conditions
Interventions
Experimental Group:Serially connect two hemoperfusion devices.
Control Group:Single hemoperfusion device
Sponsors
The first people's hospital of Foshan
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Informed Consent: - Signed and dated informed consent form from the patient or his/her legal representative. - After the patient regains consciousness, the patient's willingness to participate in the study needs to be reconfirmed. 2. Study Adherence: - Patients or their family members promise to abide by the study procedures and cooperate with the implementation of the whole process of the study. - Able to complete all follow-up visits and assessments as per the study protocol. 3. Age and Gender: - Age range: 18 years old and 70 years old. - Gender: Unlimited. 4. Diagnostic Criteria: - Meet diagnostic criteria for acute poisoning: a) Have a clear history of exposure to poisons or mising. b) Typical clinical signs and symptoms, such as nausea, vomiting, abdominal pain, dyspnea, etc., are present. c) Detection of the corresponding poison or its metabolites in blood or urine. 5. Laboratory test results: - Complete blood count: platelet count > 125 × 10^9/L - Coagulation: International normalized ratio (INR) < 1.5 6. Feasibility of the study intervention: - Able to tolerate and cooperate with gastric lavage. - No absolute contraindications to colonic lavage (e.g., intestinal obstruction, intestinal perforation, severe intra-abdominal infection, etc.). - No absolute contraindications to hemopurification therapy (e.g., severe active bleeding, hemodynamic instability, etc.). 7. Time Window: - No more than 24 hours from ingestion to medical appointment. 8. Communication Skills: - The patient or his/her legal representative is able to understand and follow the study-related instructions. - Ability to communicate effectively in a language that the researcher understands. • Note: All enrollment criteria must be met at the same time. The investigator should document the screening process for each potential subject in detail, including the reasons for failure to enroll.
Exclusion criteria
Exclusion criteria: 1. Known allergy to any drugs or materials used in the study (such as activated carbon, blood purification membrane materials, etc.). 2. Contraindications a) Recent surgical history; b) Gastrointestinal diseases (intestinal obstruction, gastrointestinal perforation, severe inflammatory bowel disease, severe liver disease [Child-Pugh Class C], esophageal and gastric varices [with bleeding risk]); c) Advanced malignant tumors (with an expected survival of less than 6 months); d) Hematologic disorders: Severe coagulation dysfunction (INR > 2.5 or platelet count < 50×10^9/L), active bleeding, or a clear tendency to bleed. 3. Other: Currently participating in another clinical trial/Other conditions deemed by the investigator as unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 28-day or hospital survival rate;Toxicity clearance rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complication rate;Total medical costs; | — |
Countries
China
Contacts
Public Contactguojun chen
The first people's hospital of Foshan
Outcome results
None listed